Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $245

Benzinga Newsdesk www.benzinga.com Positive 61.6%

Neg 0% Neu 0% Pos 61.6%

Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $225 to $245.